A 52-week, randomized, double-blind phase IIIb trial assessing the efficacy and safety of certolizumab pegol as an add-on therapy to nonbiologic DMARDs in patients with low to moderately active rheumatoid arthritis (RA) showed that addition of certolizumab pegol is effective in this setting, resulting in low disease activity or remission in most patients. However, as remission was not sustained following withdrawal of the drug, the authors recommended that certolizumab pegol be continued in patients achieving remission.
References
Smolen, J. S. et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann. Rheum. Dis. 10.1136/annrheumdis-2013-204015
Rights and permissions
About this article
Cite this article
Certolizumab pegol as an add-on therapy in RA. Nat Rev Rheumatol 10, 126 (2014). https://doi.org/10.1038/nrrheum.2014.11
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.11